HC Wainwright reaffirmed their buy rating on shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) in a research report sent to investors on Wednesday. HC Wainwright currently has a $8.00 target price on the biotechnology company’s stock.

AGTC has been the topic of a number of other research reports. Cantor Fitzgerald set a $9.00 price target on shares of Applied Genetic Technologies Corporation and gave the company a hold rating in a report on Friday, October 6th. Zacks Investment Research lowered shares of Applied Genetic Technologies Corporation from a hold rating to a sell rating in a report on Tuesday, July 11th. BMO Capital Markets reiterated an outperform rating and issued a $7.00 price target (down previously from $14.00) on shares of Applied Genetic Technologies Corporation in a report on Thursday, September 14th. ValuEngine lowered shares of Applied Genetic Technologies Corporation from a hold rating to a sell rating in a report on Friday, September 15th. Finally, Stifel Nicolaus decreased their price target on shares of Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a buy rating on the stock in a report on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $10.86.

Shares of Applied Genetic Technologies Corporation (AGTC) traded up $0.05 during midday trading on Wednesday, reaching $3.65. 184,485 shares of the company were exchanged, compared to its average volume of 172,100. Applied Genetic Technologies Corporation has a 1 year low of $3.25 and a 1 year high of $10.85.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.40). The firm had revenue of $8.30 million for the quarter, compared to analyst estimates of $12.39 million. Applied Genetic Technologies Corporation had a negative return on equity of 2.84% and a negative net margin of 8.78%. The firm’s revenue was down 31.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.15 EPS. analysts forecast that Applied Genetic Technologies Corporation will post -0.81 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/applied-genetic-technologies-corporation-agtc-receives-buy-rating-from-hc-wainwright/1691637.html.

A number of hedge funds have recently made changes to their positions in AGTC. Trexquant Investment LP grew its holdings in Applied Genetic Technologies Corporation by 3.2% during the 2nd quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 611 shares in the last quarter. Nine Chapters Capital Management LLC acquired a new position in Applied Genetic Technologies Corporation during the 3rd quarter worth $113,000. Wells Fargo & Company MN grew its holdings in Applied Genetic Technologies Corporation by 1.1% during the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 200 shares in the last quarter. Citadel Advisors LLC grew its holdings in Applied Genetic Technologies Corporation by 304.6% during the 3rd quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 31,070 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Applied Genetic Technologies Corporation during the 2nd quarter worth $178,000. 54.79% of the stock is owned by institutional investors.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.